Anzeige
Mehr »
Donnerstag, 26.02.2026 - Börsentäglich über 12.000 News
Während Washington Kupfer strategisch erklärt, schärft diese Aktie ihr Modell
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 920657 | ISIN: FR0000120578 | Ticker-Symbol: SNW
Tradegate
26.02.26 | 21:44
81,20 Euro
+0,67 % +0,54
1-Jahres-Chart
SANOFI SA Chart 1 Jahr
5-Tage-Chart
SANOFI SA 5-Tage-Chart
RealtimeGeldBriefZeit
81,0881,7122:12
81,1281,6422:00

Aktuelle News zur SANOFI Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07:38Sanofi Consumer Healthcare India Ltd leads gainers in 'A' group20
04:02Stock Alert: Lupin, Zydus Life, Shaily Engineering, KSB, Sanofi India, KP Energy, RVNL3
MiSanofi assists Boston's World Cup plans with play for local engagement6
MiFDA Approves Sanofi And Regeneron's Dupixent As First Medicine For Allergic Fungal Rhinosinusitis368PARIS (dpa-AFX) - Sanofi (SNY, SAN.PA) said FDA has approved Dupixent or dupilumab for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis...
► Artikel lesen
DiRegeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition13
DiRegeneron, Sanofi win Dupixent label expansion for allergic fungal rhinosinusitis5
DiSanofi: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis1.790Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study...
► Artikel lesen
SANOFI Aktie jetzt für 0€ handeln
MoSanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA29
MoL'Oréal Influences Sanofi CEO Ouster and Successor Appointment52
FrManuela Buxo To Become Head of Sanofi's (SNY) Specialty Care Global Business Unit21
FrSanofi sued by Texas AG for running kickback scheme for doctors8
FrTexas sues Sanofi, claiming kickbacks to doctors6
FrTexas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions29
19.02.Merck to seek 2nd-season RSV nod for Enflonsia in hot pursuit of Sanofi, AstraZeneca's Beyfortus11
19.02.Sanofi backs Altesa's $75M series B to bankroll antiviral's midstage rhinovirus study16
17.02.Sanofi - S-8, Securities to be offered to employees in employee benefit plans12
17.02.Sanofi: Filing of the 2025 U.S. Form 20-F and French "Document d'Enregistrement Universel" containing the Annual Financial Report500Filing of the 2025 U.S. Form 20-F and French "Document d'Enregistrement Universel" containing the Annual Financial Report Paris, February 17, 2026. Sanofi announces today the filing of its Form...
► Artikel lesen
17.02.Sanofi - 20-F, Annual and transition report of foreign private issuers4
17.02.JPMORGAN stuft SANOFI auf 'Neutral'870NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sanofi auf "Neutral" mit einem Kursziel von 95 Euro belassen. Analyst Richard Vosser wertete in einem am Dienstag vorliegenden...
► Artikel lesen
17.02.Sanofi bids adieu to specialty care chief, promotes Manuela Buxo to assume key post32
Weiter >>
864 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,67